DESTIN, Fla. — Rheumatoid arthritis prevention in sufferers on the subclinical or pre-clinical stage stays difficult, in accordance with a speaker on the Congress of Medical Rheumatology East annual assembly.
“You will notice people in your clinic who might be in pre-RA or within the at-risk stage of illness and this offers you some concepts for administration of them,” Kevin D. Deane, MD, PhD, William P. Arend endowed chair for rheumatology analysis on the College of Colorado Anschutz Medical Campus, and director of the College of Colorado Autoimmune Illness Prevention Heart, informed attendees.
“There isn’t a presently FDA accepted pharmacotherapy for rheumatoid arthritis prevention,” Kevin Dean, MD, PhD, informed attendees. Picture: Rob Volansky | Healio
Deane’s presentation largely centered on sufferers who had been constructive for anti-cyclic citrullinated peptide (CCP) or anti-citrullinated protein antibodies (ACPA). The primary consideration, in accordance with Deane, pertains to categorize and tackle these sufferers.
“‘In danger’ is so imprecise,” Deane mentioned. “‘Pre-RA’ or ‘pre-clinical’ can also be incorrect, relying on whether or not the affected person finally develops RA or not. The nomenclature is controversial.”
The controversy is just not restricted to clinicians and researchers hoping to outline the phrases. Telling a affected person they’ve a swollen joint or synovitis, even when it doesn’t finally evolve into RA, could be important.
“People who’re in danger for RA can get slightly bit bizarre about it,” Deane mentioned. “They’ve a brand new relationship with these new signs. They could be in denial as soon as they’ve a swollen joint, and so they might not come see us. It’s tough.”
Schooling is essential in these instances, in accordance with Deane.
“I give pretty intensive training about what RA is and what signs are,” he mentioned.
Schooling also can function details about life-style elements.
“We ask individuals to quit smoking issues if they’ll do it,” Deane mentioned.
Train, a nutritious diet and periodontal well being are additionally advisable.
“You will have heard that periodontal illness is a threat issue for future RA,” Deane mentioned. “At greatest, it’s controversial.”
He later recommended that improved periodontal well being is probably going helpful for the affected person’s well being no matter whether or not it could actually forestall RA or not.
One other concern for pre-RA administration is the dearth of choices for these sufferers, in accordance with Deane.
“There isn’t a presently FDA accepted pharmacotherapy for RA prevention,” he mentioned.
Within the absence of medicines, Deane provided some pointers for approaching sufferers on this ambiguous territory. Step one, he mentioned, is to conduct an intensive bodily examination.
“The gold customary for diagnosing rheumatoid arthritis remains to be a bodily examination,” he mentioned.
Imaging can assist detect synovitis, however challenges stay for this method, as effectively, in accordance with Deane.
“We might get to the purpose the place MRI or ultrasound is the gold customary, however we’re not there but,” he mentioned.
Furthermore, even when subclinical synovitis is detected on imaging, it doesn’t essentially imply that the affected person will progress to RA or have persistent illness or signs.
No matter what the interval earlier than RA growth known as and the way the signs are assessed and identified, Deane burdened that early intervention is essential.
“Should you catch somebody inside weeks or months of the primary swollen joint, they do a lot better than for those who catch them after years,” he mentioned. “Let’s not await individuals to get sick.”
Sources/Disclosures
Collapse
Deane Okay. Therapeutic Intervention in RA: When and Which Drug? Is It Potential to Stop Clinically Impactful Illness? Introduced at The Congress of Medical Rheumatology East; Might 1-4, 2025; Destin, Florida (hybrid assembly).
Disclosures:
Deane reviews receiving grant funding from Boehringer Ingelheim, Gilead and ThermoFisher, and consulting for Bristol Myers Squibb, ThermoFisher and Werfen/Inova Diagnostics.
